Abcam PLC
LSE:ABC
Abcam PLC
Revenue
Abcam PLC
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abcam PLC
LSE:ABC
|
Revenue
£350.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
14%
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Revenue
$6.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Revenue
$1.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Revenue
$27m
|
CAGR 3-Years
37%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Revenue
£249.4m
|
CAGR 3-Years
102%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Revenue
£673.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
See Also
What is Abcam PLC's Revenue?
Revenue
350.4m
GBP
Based on the financial report for Jun 30, 2022, Abcam PLC's Revenue amounts to 350.4m GBP.
What is Abcam PLC's Revenue growth rate?
Revenue CAGR 10Y
14%
Over the last year, the Revenue growth was 18%. The average annual Revenue growth rates for Abcam PLC have been 10% over the past three years , 10% over the past five years , and 14% over the past ten years .